News About: Pharm. Industry
Celltrion Group to decide final location to construct Factory 3 in another countryCelltrion Chairman Jung-Jin Seo released its next-gen pipelines and global market strategies that were planned to carry out by 2030 at the ‘2018 Celltrion Healthcare Internation...
|
Hanmi CEO Sae-Chang Kwon, “We applied FDA approval for Rolontis and Olita’s Phase III clinical trial”Hanmi Pharm(CEO Sae-Chang Kwon) has set the ‘Hanmi Innovative Management to Become Pharmaceutical Power’ ’as their new year’s resolution.
“During my more than 20-year career at...
|
Celltrion Chairman Jung-Jin Seo will reveal pipelines to be developed by 2030Celltrion Chairman Jung-Jin Seo will reveal its pipelines at the 2018 Celltrion Healthcare International Summit in Venice, Italy between the 8th and 9th of February.
The Celltr...
|
Novartis rebate case, how far PMs could do?As it seemed PMs for marketing have exchanged money directly with the media companies involved with the Novartis’ rebate case, the people are focusing on the relations among the...
|
Sanofi, “We’ll start 2 new Phase III clinical trials of Hanmi’s efpeglenatide this year”
Hanmi Pharm(CEO Sae-Chang Kwon, Jong-Soo Woo) will conduct 2 more new Phase III clinical trials to increase the value of efpeglenatide, a new antidiabetic biologic.
A partnering company of Hanmi Pharm, Sanofi announc...
KCDC-CJ sign technology transfer agreement of hand-foot and mouth disease vaccine worth of KRW 2.2 billion
The Korea Centers for Disease Control and Prevention(KCDC) Korea National Institute of Health(President Do-Joon Park) will sign a technology transfer agreement of a preventive hand-foot and mouth disease injectable va...
“Adopting QbD is not a choice, but requirement for pharma industry”
As a method to narrow the technology gap against pharmaceutically-advanced countries and increase the Korea’s national competitiveness of medicines developed in Korea, the Ministry of Food and Drug Safety(MFDS) will a...
Dong-A ST completes constructing biologic factory in Indonesia to enter its market
Dong-A ST will speed up the process to enter the rapidly-growing Indonesian market by completing the construction of its biologic manufacturing factory.
Dong-A ST(CEO/Vice President Soo-Hyung Kang) announced on the 6...
Hanmi Pharm applies for U.S. approval new biologic ‘Rolontis’ in 4th quarter
Hanmi Pharm is expected to apply for commercialization approval for a new biologic developed by Hanmi Pharm(CEO Sae-Chang Kwon and Jong-Soo Woo) for the treatment of persistent neutropenia, Rolontis, in the U.S. this ...
MRs having difficulties in meeting with doctors, bringing huge negative impacts on sales
Beginning this January, the ‘Financial Gain & Expenditure Report’ has started to bring impacts in the industry.
Unlike the expectation that the industry would start to adapt to the enforcement after confusion only in...
